ArQule, Inc.
(NASDAQ : ARQL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
-0.45%168.840.4%$364.73m
VRXValeant Pharmaceuticals International, Inc.
-0.32%22.0714.1%$216.52m
PRGOPerrigo Co. Plc
-0.11%76.136.7%$103.64m
JAZZJazz Pharmaceuticals Plc
-0.66%166.402.2%$88.38m
PTLAPortola Pharmaceuticals, Inc.
-0.63%41.107.7%$80.74m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-0.91%153.297.6%$74.84m
SAGESAGE Therapeutics, Inc.
1.66%166.999.6%$73.72m
MNKMallinckrodt Plc
1.85%15.9921.1%$57.14m
SUPNSupernus Pharmaceuticals, Inc.
-2.90%54.486.3%$47.06m
UTHRUnited Therapeutics Corporation
-1.50%104.6814.4%$39.69m
PBHPrestige Brands Holdings, Inc.
-0.18%34.243.8%$39.48m
ICPTIntercept Pharmaceuticals, Inc.
-1.72%71.2121.8%$35.12m
CTLTCatalent Inc
0.85%40.562.6%$32.49m
HZNPHorizon Pharma plc
-0.76%15.007.5%$29.55m
IRWDIronwood Pharmaceuticals, Inc. Class A
-0.61%17.9710.2%$27.96m

Company Profile

ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of targeted therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751, ARQ 761. The company was founded in 1993 and is headquartered in Burlington, MA.